Good Health Can’t Wait.
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Corporate Overview Annual Report 2014 - 15<br />
Given that VUR is rare, its treatment<br />
options are few and inconvenient. They<br />
include antibiotics and surgery that<br />
involve long hospital stay and painful<br />
procedures. Not only is this difficult for<br />
children under six, it is also an expensive<br />
proposition.<br />
At Dr. Reddy’s, we believe limited<br />
treatment options should not be a hurdle<br />
to care. Even for rare diseases that affect<br />
only a few people, our aim is to respond<br />
with urgency to offer affordable and<br />
innovative solutions.<br />
A safe, affordable alternative approach to<br />
treating VUR, therefore, became a mission<br />
for us.<br />
Following extensive research and<br />
coordination with multiple teams, we<br />
tied up with Oceana Therapeutics Inc.<br />
to import Deflux®, a minimally invasive<br />
endoscopic injection to treat Grade II-IV<br />
VUR effectively with 80-90% success rate.<br />
It provides a higher level of protection<br />
against infection, compared to antibiotics,<br />
and has an excellent safety profile.<br />
Independent studies also established that<br />
there was nearly a four-fold reduction in<br />
Deflux®<br />
A minimally invasive<br />
endoscopic injection<br />
to treat Grade II-IV<br />
VUR effectively with<br />
80-90% success rate.<br />
VUR associated infections<br />
compared with antibiotics.<br />
It also helps to reduce the<br />
need of invasive surgical<br />
procedure.<br />
Our next step was to make pediatric<br />
surgeons aware of the availability of a<br />
viable therapy and also train them in its<br />
proper use. We organized special crossspecialty<br />
meetings for pediatricians<br />
and pediatric surgeons to inform<br />
doctors of the benefits of<br />
the drug and facilitate<br />
early diagnosis. We<br />
also collaborated with<br />
Olympus (a medical<br />
device company) to<br />
provide pediatric<br />
surgeons with<br />
an expensive<br />
device used for<br />
injecting Deflux®.<br />
As a result, we<br />
have been able<br />
to treat more than<br />
280 children in<br />
India till date.<br />
>280<br />
children in India treated<br />
Dr. Reddy’s tied up with<br />
Oceana Therapeutics Inc.<br />
to import Deflux®.<br />
Small children can now<br />
smile more. VUR can be<br />
effectively managed, as<br />
the treatment is faster, less<br />
painful and more affordable<br />
– an encouraging reality for<br />
doctors and families of the<br />
affected children.<br />
13